JPMorgan Chase & Co. Has $15.69 Million Position in Omnicell, Inc. $OMCL

Key Points

• JPMorgan Chase cut its stake in Omnicell by 94.2%, selling 8,362,010 shares and leaving the firm with 515,352 shares worth about $15.69 million (1.15% of the company).
• Analyst coverage is mixed but leans positive: Omnicell has a consensus rating of “Moderate Buy” with an average target of $58.50, including notable buy targets from Bank of America ($70) and UBS ($60) alongside downgrades and price-target cuts from others.
• Omnicell recently missed EPS (reported $0.40 vs. $0.47 expected) while revenue was roughly in line, and it set FY 2026 guidance at $1.65–$1.85 EPS.

JPMorgan Chase & Co. cut its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 94.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 515,352 shares of the company's stock after selling 8,362,010 shares during the quarter. JPMorgan Chase & Co. owned 1.15% of Omnicell worth $15,692,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in shares of Omnicell in the second quarter valued at approximately $26,000. First Horizon Corp bought a new position in Omnicell in the 3rd quarter valued at approximately $31,000. Farther Finance Advisors LLC boosted its position in Omnicell by 784.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company's stock worth $36,000 after buying an additional 1,036 shares during the period. LSV Asset Management bought a new stake in Omnicell during the 3rd quarter worth approximately $97,000. Finally, Tower Research Capital LLC TRC grew its holdings in Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock worth $146,000 after acquiring an additional 3,932 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on OMCL shares. Piper Sandler reaffirmed an "overweight" rating and set a $49.00 price target (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Weiss Ratings cut shares of Omnicell from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, March 2nd. UBS Group set a $60.00 price objective on Omnicell and gave the company a "buy" rating in a report on Friday, March 13th. Zacks Research raised Omnicell from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. Finally, Bank of America raised Omnicell from a "neutral" rating to a "buy" rating and set a $70.00 target price on the stock in a report on Wednesday, February 4th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Omnicell presently has a consensus rating of "Moderate Buy" and an average target price of $58.50.

Omnicell Stock Up 0.7%

Omnicell stock opened at $35.20 on Friday. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of 880.22, a PEG ratio of 1.25 and a beta of 0.79. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. The firm has a 50 day moving average price of $41.00 and a two-hundred day moving average price of $38.53.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing analysts' consensus estimates of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. During the same period in the prior year, the company posted $0.60 earnings per share. The company's revenue for the quarter was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Corey J. Manley sold 7,405 shares of Omnicell stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the transaction, the executive vice president directly owned 96,717 shares of the company's stock, valued at approximately $3,355,112.73. This trade represents a 7.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.52% of the company's stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.